Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin-based versus clarithromycin-based therapy for Helicobacter pylori eradication
IRCT20240128060832N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of moxifloxacin, clarithromycin, amoxicillin and pantoprazole in Helicobacter pylori infection (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Eradication, Drug side effects and 4 more. Started Mar 2024; status: completed.
02
Drugs
moxifloxacinclarithromycinamoxicillinpantoprazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20240128060832N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240128060832N1.